Update of FDA Review of Acadia's Nuplazid

To continue Pierre77's topic from another thread.  Today's update on Acadia's Parkinson's Psychosis Drug:  the FDA's comments before independent adcomm recommendation scheduled for tomorrow. The Street (AF) gives FDA's current more critical comments.   Excerpt:

"Acadia's market value has shrunk along with the rest of the biotech sector since last summer. But the stock has also come under selling pressure because of investor concerns which echo the FDA's Nuplazid review. Nuplazid could be good enough to get approved, but minimal efficacy and questionable safety raise the risk that its use -- and sales -- will be limited."

http://www.thestreet.com/story/1350...-of-tuesday-panel.html?puc=yahoo&cm_ven=YAHOO